Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).

Medical oncology (Northwood, London, England) - 1 Apr 2015

Li Jian, Dang Yunzhi, Gao Jing, Li Yanyan, Zou Jianling, Shen Lin

Abstract excerpt

Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) pathway activation may be related to imatinib resistance; however, no study has focused on whether signal conduction of this pathway will change after imatinib resistance. A total of 111 GIST samples from 91 patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastrointestinal Stromal Tumors
Share to Imatinib Mesylate
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lymphatic Metastasis

Share to Proto-Oncogene Proteins c-akt

Share to Proto-Oncogene Proteins c-kit

Share to PTEN Phosphohydrolase

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 25757539
DOI: 10.1007/s12032-015-0554-6

Genes

KIT
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25757539-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).PMID 25757539Read ↗

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

[Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].Semantic proximity Read ↗

Establishment of the prediction model and biological mechanism exploration for secondary imatinib-resistant in gastrointestinal stromal tumor.Semantic proximity Read ↗

New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.Semantic proximity Read ↗

The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.Semantic proximity Read ↗

Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal TumorSemantic proximity Read ↗

SGPL1 Deficiency Get Involved in Imatinib Resistance via PI 3 K-Akt signaling pathway in gastrointestinal stromal tumorSemantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

Long‐term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN geneSemantic proximity Read ↗

Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.Semantic proximity Read ↗

PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.